Novocure Ltd. shares surged 49.4% in morning trade Monday after the company said its late-stage clinical trial in newly diagnosed glioblastoma showed positive results. Novocure found that the two-year survival rate for patients improved from 30% to 43% after its drug Optune was added to standard temozolomide chemotherapy, and the five-year survival rate increased from ...
The post Novocure Ltd. stock surges nearly 50% after positive late-stage trial results in brain cancer appeared first on ForexTV.
April 04, 2017 at 04:13AM
http://ift.tt/2nULb4U
from Market Watch
http://ift.tt/2nULb4U
No comments:
Post a Comment